

Laparoscopic sphincter-preserving surgery (intersphincteric resection) after neoadjuvant imatinib treatment for gastrointestinal stromal tumor (GIST) of the rectum

Yoshiya Fujimoto · Takashi Akiyoshi · Tsuyoshi Konishi · Satoshi Nagayama · Yosuke Fukunaga · Masashi Ueno

Accepted: 29 August 2013 / Published online: 10 September 2013
© Springer-Verlag Berlin Heidelberg 2013

Abstract

Background Gastrointestinal stromal tumors (GISTs) of the rectum are rarely found, and radical surgery such as abdominoperineal resection would be necessary for large rectal GIST. On the other hand, therapy for GIST has changed significantly with the use of imatinib. Neoadjuvant imatinib therapy may reduce tumor size and may potentially prevent extended surgery. Moreover, when sphincter-preserving surgery is carried out laparoscopically, it can be performed as minimally invasive surgery with preservation of the anus.

Methods From 2008 to 2011, five patients with rectal GIST were treated in our hospital. All patients received preoperative imatinib treatment (400 mg/day) and underwent laparoscopic sphincter-preserving surgery after 4–12 months of this treatment.

Results Initial median tumor size was 31 mm (range, 24–88). At the time of operation, the median tumor size was 24 mm (range, 11–52). Sphincter-preserving surgery was performed in all patients. Three patients underwent laparoscopic intersphincteric resection (ISR), and two patients underwent transanal full-thickness local resection and recto-anal anastomosis following laparoscopic ISR. Macroscopically complete resection was achieved, and microscopically, the resection margin was not involved of residual tumors. The median duration of postoperative hospital stay was 16 days (range, 13–30). No recurrence occurred in all patients during 1 to 4 years.

Conclusions The present study suggests that neoadjuvant imatinib therapy might be effective to prevent extended surgery for rectal GIST, and laparoscopic sphincter-preserving

surgery is safe and technically feasible. We recommend a combination of neoadjuvant imatinib therapy and laparoscopic ISR for locally advanced rectal GIST.

Keywords Sphincter-preserving surgery · ISR · Imatinib · Rectal GIST

Introduction

Gastrointestinal stromal tumor (GIST) is the most common mesenchymal malignancy found in the GI tract. GISTs most often arise in the stomach but may also be found in the rectum (approximately 5 %) [1]. Surgery is the first choice treatment for a resectable GIST, and complete surgical resection is the most effective treatment to reduce the rate of recurrence and to improve the outcome [2]. Radical surgery such as abdominoperineal resection (APR) or more extended surgery which necessitate the removal of adjacent organs would be necessary for locally advanced rectal GIST located very close to the anus.

Imatinib, a small molecule inhibitor of the oncoprotein KIT and PDGFRA, has become the standard treatment for recurrent or metastatic GISTs [3, 4]. There are few reports of preoperative imatinib treatment for unresectable or locally advanced primary GISTs [5, 6]. Only few reports have described using imatinib as a neoadjuvant treatment for rectal GIST [7, 8]. Imatinib treatment leads to reduced tumor size, improving the chances of complete surgical resection and the preservation of function.

On the other hand, extended indication for laparoscopic surgery is a recent breakthrough in the field of rectal cancer surgery. Our previous report also showed that laparoscopic surgery for rectal cancer is technically feasible [9], and laparoscopic intersphincteric resection (ISR) for very low rectal

Y. Fujimoto (✉) · T. Akiyoshi · T. Konishi · S. Nagayama · Y. Fukunaga · M. Ueno

Department of Gastroenterological Surgery, Cancer Institute Hospital, 3-8-31, Ariake, Koto-ku, Tokyo 135-8550, Japan
e-mail: yoshiya.fujimoto@jfcf.or.jp

cancer is technically feasible and a safe alternative to laparotomy with favorable short-term postoperative outcomes [10].

We now report five patients who were treated by a combination of neoadjuvant imatinib therapy and laparoscopic sphincter-preserving surgery (ISR or modified ISR) for a large rectal GIST.

Patients and methods

From 2008 to 2011, five patients with rectal GIST were treated in our hospital. Colonoscopy (CS), endorectal ultrasonography (EUS), computed tomography (CT), and magnetic resonance imaging (MRI) were performed in all patients. CS and EUS were used to evaluate tumor size and distance to anal verge. A biopsy of the tumor showed spindle cells with immunoperoxidase stains positive for c-kit, leading to the histological diagnosis of a GIST. CT and MRI were used to evaluate tumor size, tumor invasion, and lymph node metastasis. All tumors were initially considered to be too large or difficult to remove including resection margin which was negative when the surgery of preserving function was performed. All patients declined a recommendation to receive an APR or extend surgery due to complete surgical resection.

We expect that neoadjuvant imatinib therapy may reduce tumor size and may potentially prevent extended surgery, and then, all patients received preoperative imatinib treatment (400 mg/day). CS and CT (or MRI) were used repeatedly every 3–6 months to measure a tumor response to imatinib treatment. The indication to discontinue preoperative treatment was lack of reduce in tumor size measured clinically. The resectability was determined by CT or MRI. All patients underwent laparoscopic sphincter-preserving surgery after neoadjuvant imatinib therapy.

After surgery, patients were followed up included regular visits every 3 months. Clinical examination and CT were obtained every 6 months, and CS was received every 12 months. Postoperative imatinib was given in selected patients for 2 or 3 years. Local and distant recurrences were defined by radiographic and histological findings.

Results

The patient and tumor characteristics are presented in Table 1. The median age was 58 years (range, 33–76), and four were male, and one was female. Initial median tumor size was 31 mm (range, 24–88). The distance from anal verge to the lower margin of the tumor was 3 cm (range, 2–5). At the time of operation, the median tumor size was 24 mm (range, 11–52). Side effect of edema occurred in three patients, who recovered with conservative therapy by reducing the quantity of imatinib. The suspicious tumor invasion to adjacent organs

Table 1 Clinical features and outcome of surgical resection

No.	Age (years)	Sex	Duration of imatinib therapy (months)	Tumor size (mm)		Distance from anal edge (cm)	Surgery	Surgical margins	Pathological tumor size (mm)	Postoperative imatinib therapy	Status	Last follow-up (months)
				Before	After							
1	46	M	4	88	48	4	ISR	R0	55	Yes	ANED	51
2	62	M	11	31	24	3	Modified ISR	R0	24	No	ANED	36
3	33	F	12	70	52	5	ISR	R0	65	Yes	ANED	37
4	76	M	6	28	11	3	Modified ISR	R0	0 (p-CR)	No	ANED	18
5	58	M	10	24	12	2	ISR	R0	20	Yes	ANED	13

ISR intersphincteric resection, R0 surgical complete resection with negative microscopic margins, ANED alive with no evidence of disease, p-CR pathological complete response

(such as the prostate or the vagina or the levator ani muscle) has improved to clear margin by CT or MRI. MRI of the pelvis revealed reduction in tumor size (Figs. 1 and 2). We were enabled to complete surgical resection including the possibility of obtaining more safety margin.

All patients underwent laparoscopic sphincter-preserving surgery after 4–12 months of neoadjuvant imatinib therapy. Three patients underwent laparoscopic ISR, and two patients underwent laparoscopic modified ISR. ISR was partial ISR but not total ISR. Modified ISR starts with mobilizing the rectum with preserving the superior rectal artery. Next, transanal intersphincteric dissection and extraction of the rectum through the anus is performed. Finally, full-thickness local resection under the direct vision and reconstruction by recto-anal anastomosis is performed. A diverting ileostomy was created in all cases. The median operation time was 269 min (range, 155–352), and the median estimated blood loss was 115 ml (range, 30–340). We did not have any intraoperative complications. Macroscopically complete resection was achieved in all patients. There was no mortality. Postoperative complication occurred in one patient (ileus) but recovered with conservative therapy. The median duration of postoperative hospital stay was


16 days (range, 13–30). Microscopically, the resection margin was not involved by residual tumors. One patient achieved complete response. An ileostomy was closed in all patients after 3–5 months.

The median follow-up period was 36 months (range, 13–51). No recurrence occurred in all patients during 1 to 4 years. Postoperative imatinib was given in three patients; one patient was treated after a year of surgery, and the other two patients were still treated continuously at the present time. The satisfaction of patients was good because preservation of quality of life by avoiding a permanent stoma. The bowel function was kept well; the daily stool frequency was four to five times, and the fecal incontinence did not arise. Bladder function was satisfactory because urinary retention or urinary disturbance occurred in no patient. Sexual function was not evaluated due to lack of research.

Discussion

The complete surgical resection is the most effective treatment for GIST to reduce the rate of recurrence and to improve the

Fig. 1 Magnetic resonance images obtained before (*a1*, *a2*) and after (*b1*, *b2*) treatment with imatinib therapy (case 1)



outcome. Until more effective adjuvant therapy becomes available, the treatment of GISTs will remain primarily surgical, because recurrence occurred in 40 % of patients who underwent complete resection, and the disease-specific survival rate was 54 % at 5 years [2]. Imatinib has been demonstrated to be a very active agent for tumor control in GIST [11]. Clinical trials have shown that about 50 % of patients with a metastatic GIST will have a partial response to imatinib, and about 80 % will at least have stable disease, and thus, imatinib is now considered as the first-line treatment for metastatic GIST [3, 4]. In unresectable or locally advanced primary GISTs, preoperative imatinib is a useful tool both to improve resectability and to reduce surgical morbidity because patients had tumor shrinkage with a median tumor size reduction of 34 % after imatinib treatment [5]. A formal indication to imatinib in a localized unresectable GIST had already been provided, and it is consistently proposed by all available guidelines [12, 13]. The Radiation Therapy Oncology Group (RTOG) was a prospective phase II study (RTOG 0132) evaluating safety and efficacy of neoadjuvant imatinib for patients with locally advanced primary GIST (response was 7 % partial and 83 % stable, and complications of surgery and imatinib toxicity were minimal); this approach is feasible [6].

Because rectal GISTs are rare, little data are available. Dematteo et al. [14] describe the poor outcome of colorectal GIST compared with gastric or small bowel tumors.

Furthermore, because rectal GISTs are often large tumors, resection can be difficult. In general, the resectability of a large tumor is hard to standardize and is often considered to be surgeon dependent. The indication of a neoadjuvant imatinib therapy for locally large GIST hopes to become universally acceptable resection. In the case of rectal GIST using imatinib as a neoadjuvant therapy, there were particularly only few cases (one of 30 cases in RTOG 0132 trial [6] and 4 of 15 cases in Fiore et al. [5]). Only a few case reports have described using imatinib as a neoadjuvant therapy for rectal GIST [15–19], and all case reports underwent complete surgery after downsizing of tumor. Similar surgical managements following neoadjuvant therapy have been described in the report of three patients [7] and nine patients [8]. The neoadjuvant imatinib therapy might increase an opportunity of complete resection and, moreover, might preserve function. In our cases, all patients underwent complete surgical resection macroscopically and microscopically including one complete response case, avoiding a radical excision and preserving the anus.

The optimal duration of preoperative imatinib for patients with locally advanced GIST is unknown. Median time to secondary progression during primary treatment with imatinib has been shown to be approximately within 10 months to 2 years [2, 4, 20]. The median time to best response in all responding patients was about 4 months (107 days), and most




Fig. 2 Magnetic resonance images obtained before (*c1*, *c2*) and after (*d1*, *d2*) treatment with imatinib therapy (case 3)

responses happened in 9 months of treatment [4]. Therefore, it seems quite reasonable to place surgery around 1 year from the start of treatment [21, 22]. Several reports described that patient received surgery after 1.5–3 months of neoadjuvant therapy [7, 15, 17–19]. Verweij et al. [4] recommend that studies on neoadjuvant therapy should be designed with duration of treatment ranging from 4 to 6 months. Because complete pathological response of pelvic GIST was obtained after 12 months with imatinib as neoadjuvant therapy, they could be extended up to 1 year [16]. In our cases, surgery was placed after 4–12 months of treatment. Since resistance to relevant secondary mutation may be observed after neoadjuvant imatinib therapy, the time elapse with preoperative imatinib therapy should be chosen shortly as complete resection can be carried out.

Laparoscopic surgery becomes increasingly feasible not only for abdominal surgical procedures but also for thoracic and soft tissue procedures. Laparoscopic surgery is minimally invasive and useful for the treatment of a rectal tumor [9, 10]. Few reports have been published on the potential benefits of laparoscopic surgery for rectal GIST [17, 19]. Our cases presented here underwent a laparoscopic surgery, and the resection margins were macroscopically and microscopically not involved by residual tumors. Although rectal surgery generally presents major technical difficulties, a magnified view obtained by laparoscopy provides a more precise image of dissection. Laparoscopic surgery is also advantageous in sufficiently mobilizing the lower rectum from the pelvic floor with a good view, and even the dissection of the intersphincteric groove can be performed exactly. Laparoscopic ISR would be beneficial to patients concerning the oncological quality of operation [10]. When the rectal dissection is laparoscopically performed until the level of intersphincteric groove, the transanal intersphincteric dissection and pull of the tumor from anus and then complete resection could be underwent with certain safety margin under a direct view. This approach has advantages for large GIST, including the possibility of obtaining more safety margin than transanal approach, and preserving the function of the anal sphincter avoided a permanent stoma. Although transanal local resection approach is effective in small GIST less than 1 cm, it is unsuitable for a large GIST. Furthermore, transanal local resection approach is difficult to secure with an appropriate resection margin when GIST is in contact with adjacent organs such as the prostate or vagina. In our cases, microscopically, the resection margin was not involved of residual tumors. The satisfaction of patients was good because the quality of life was preserved, and no recurrence occurred.

In conclusion, we reported that neoadjuvant imatinib therapy in locally advanced rectal GIST is safe and effective, and shrinkage of tumor is expected with a clear benefit for the local treatment. It is often reasonable to consider a possible combination of imatinib therapy and surgical resection, especially

laparoscopic ISR for minimally invasive surgery with preservation of the anus. However, we admit that this study includes a small number of cases, and we recommend a combination of neoadjuvant imatinib therapy and laparoscopic ISR for locally advanced rectal GIST.

Conflict of interest We have no conflicts of interest or financial ties to disclose.

References

1. Tran T, Davila JA, El-Serag HB (2005) The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000. *Am J Gastroenterol* 100:162–168
2. Dematteo RP, Lewis JJ, Leung D et al (2000) Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. *Ann Surg* 231:51–58
3. Demetri GD, von Mehren M, Blanke CD et al (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. *N Engl J Med* 347:472–480
4. Verweij J, Casali PG, Zalcberg J et al (2004) Progression-free survival in gastrointestinal stromal tumors with high-dose imatinib: randomized trial. *Lancet* 364:1127–1134
5. Fiore M, Palassini E, Fumagalli E et al (2009) Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST). *Eur J Surg Oncol* 35:739–745
6. Eisenberg BL, Harris J, Blanke CD et al (2009) Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors (GIST): early results of RTOG 0132/ACRIN 6665. *J Surg Oncol* 99:42–47
7. Wang JP, Wang T, Huang MJ et al (2011) The role of neoadjuvant imatinib mesylate therapy in sphincter-preserving procedures for anorectal gastrointestinal stromal tumor. *Am J Clin Oncol* 34:314–316
8. Machlenkin S, Pinsk I, Tulchinsky H et al (2011) The effective of neoadjuvant imatinib therapy on outcome and survival after rectal gastrointestinal stromal tumour. *Color Dis* 13:1110–1115
9. Kuroyanagi H, Oya M, Ueno M, Fujimoto Y, Yamaguchi T, Muto T (2008) Standardized technique of laparoscopic intracorporeal rectal transection and anastomosis for low anterior resection. *Surg Endosc* 22:557–561
10. Fujimoto Y, Akiyoshi T, Kuroyanagi H et al (2010) Safety and feasibility of laparoscopic intersphincteric resection for very lower rectal cancer. *J Gastrointest Surg* 14:645–650
11. Joensuu H, Roberts PJ, Sarlom-Rikala M et al (2001) Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. *N Engl J Med* 344:1052–1056
12. Casali PG, Jost L, Reichardt P, Schlemmer M, Blay JY, ESMO Guideline Working Group (2008) Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. *Ann Oncol* 19(Suppl 2):ii35–ii38
13. Demetri GD, Benjamin RS, Blanke CD et al (2007) NCCN task force report: management of patients with gastrointestinal stromal tumor (GIST)—update of the NCCN clinical practice guidelines. *JNCCN* 5(Suppl 2):S1–S29
14. Dematteo RP, Gold JS, Saran L et al (2008) Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). *Cancer* 112:608–615

15. Lo SS, Papachristou GI, Finkelstein SD et al (2005) Neoadjuvant imatinib in gastrointestinal stromal tumor of rectum: report of a case. *Dis Colon Rectum* 48:1316–1319
16. Salazar M, Barata A, Andre S et al (2006) First report of a complete pathological response of a pelvic GIST treated with imatinib as neoadjuvant therapy. *Gut* 55:585–586
17. Ebihara Y, Okushiba S, Kawarada Y et al (2008) Neoadjuvant imatinib in a gastrointestinal stromal tumor of the rectum: report of a case. *Surg Today* 38:174–177
18. Hou YY, Zohu Y, Lu SH et al (2009) Imatinib mesylate neoadjuvant treatment for rectal malignant gastrointestinal stromal tumor. *World J Gastroenterol* 15:1910–1913
19. Nakamura T, Mitomi H, Onozato W et al (2012) Laparoscopic resection of a gastrointestinal stromal tumor of the rectum after treatment with imatinib mesylate: report of a case. *Surg Today* 42: 1096–1099
20. Haller F, Detken S, Schulten HJ et al (2007) Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations. *Ann Surg Oncol* 14:526–532
21. Blay JY, Bonvalot S, Casali P, GIST consensus meeting panelists et al (2005) Consensus meeting for gastrointestinal stromal tumours. Report of the GIST consensus conference of 20–21 March 2004, under the auspices of ESMO. *Ann Oncol* 16: 566–578
22. Gronchi A, Fiore M, Miselli F et al (2007) Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advance/metastatic GIST. *Ann Surg* 245:341–346